Takuya Akashi: Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. akashi@med.u-toyama.ac.jp
The chemokine receptorCXCR4 has been reported to be aberrantly expressed in humancancers and has also been shown to participate in the development of cancer metastasis. The present study was carried out to assess immunohistochemically the pattern of CXCR4 expression in patients with metastatic prostate cancer. We analyzed whether there may be an association between CXCR4 expression and prognosis. Fifty-two patients who received hormonal therapy were enrolled. Specimens were obtained from transperineal needle biopsy before treatment, and were stained with antihuman CXCR4 antibody. We also evaluated the pathological grade, extent of bony metastasis, clinical response to hormonal therapy, and patient prognosis. CXCR4 was detected in 94.2% patients. Its expression showed no association with pathological grade, extent of bony metastasis, or clinical response to hormonal therapy. patients with a high expression of CXCR4 in tumors had poorer cancer-specific survival than those with low expression of CXCR4. CXCR4 expression is a useful prognostic factor for patients with metastatic prostate cancer treated with androgen-withdrawal therapy.
References
J Immunol. 2001 Oct 15;167(8):4747-57
[PMID: 11591806]
Biochem Biophys Res Commun. 2004 Jul 30;320(3):656-63
[PMID: 15240098]
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8
[PMID: 14595012]
